Revenue Recognition Segment revenue by major payor (Tables)

6 Months Ended

Jun. 30, 2025

Disaggregation of Revenue [Table Text Block]

The following tables summarize the Company's segment revenues by primary payor source:


	Three months ended June 30, 2025						Three months ended June 30, 2024
	U.S. dialysis		Other — Ancillary services		Consolidated		U.S. dialysis		Other — Ancillary services		Consolidated
Dialysis patient service revenues:
Medicare and Medicare Advantage	$	1,659,607	$		$	1,659,607	$	1,587,198	$		$	1,587,198
Medicaid and Managed Medicaid	217,699				217,699		214,951				214,951
Other government	83,104		224,937		308,041		80,338		176,524		256,862
Commercial	947,015		91,225		1,038,240		952,625		62,391		1,015,016
Other revenues:
Medicare and Medicare Advantage			140,149		140,149				97,433		97,433
Medicaid and Managed Medicaid			—		—				445		445
Commercial			8,322		8,322				10,200		10,200
Other(1)	5,966		21,054		27,020		5,898		15,467		21,365
Eliminations of intersegment revenues	(16,716)		(2,836)		(19,552)		(12,925)		(3,823)		(16,748)
Total	$	2,896,675	$	482,851	$	3,379,526	$	2,828,085	$	358,637	$	3,186,722


	Six months ended June 30, 2025						Six months ended June 30, 2024
	U.S. dialysis		Other — Ancillary services		Consolidated		U.S. dialysis		Other — Ancillary services		Consolidated
Dialysis patient service revenues:
Medicare and Medicare Advantage	$	3,268,625	$		$	3,268,625	$	3,118,696	$		$	3,118,696
Medicaid and Managed Medicaid	424,208				424,208		425,075				425,075
Other government	159,850		435,301		595,151		162,924		322,309		485,233
Commercial	1,871,903		178,427		2,050,330		1,878,455		132,564		2,011,019
Other revenues:
Medicare and Medicare Advantage			239,103		239,103				200,542		200,542
Medicaid and Managed Medicaid			2		2				841		841
Commercial			11,023		11,023				17,140		17,140
Other(1)	11,974		36,654		48,628		12,021		30,669		42,690
Eliminations of intersegment revenues	(28,450)		(5,565)		(34,015)		(37,389)		(6,570)		(43,959)
Total	$	5,708,110	$	894,945	$	6,603,055	$	5,559,782	$	697,495	$	6,257,277

(1) Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.